Immutep says TACTI-004 to be discontinued following futility analysis

Immutep Limited announced the discontinuation of its TACTI-004 trial after a futility analysis. This decision follows a review of efficacy and safety data, which also caused the company’s shares to hit an all-time low. Immutep is a biotechnology company focused on developing LAG-3 immunotherapies for cancer and autoimmune diseases.